MINNEAPOLIS, Feb. 1 (HSMN NewsFeed) -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced the appointment of Xavier Bertrand to the position of Vice President and General ...
Devices, Personnel
ATS Medical

ANDOVER, Mass., Feb. 1 (HSMN NewsFeed) -- Smith & Nephew's (NYSE: SNN); (LSE: SN) Endoscopy Division today announced that the company has been awarded a three-year contract (effective February 15, 2010) from HealthTrust Purchasing Group as a supplier of ...
Devices, Group Purchasing
Smith & Nephew, HealthTrust Purchasing Group, DYONICS

Results Published in EuroIntervention Show Low MACE and Thrombosis Rates in Patients Treated with Genous Stent FORT LAUDERDALE, Fla., Feb. 1 (HSMN NewsFeed) -- OrbusNeich announced today that data published in EuroIntervention (EuroIntervention, 2010;...
Devices, Interventional Cardiology
OrbusNeich, STEMI , Genous Bio-engineered R stent

Strategic Acquisition Broadens Blood Management Software Solutions to Customers across the Blood Supply Chain EL DORADO HILLS, Calif., BRAINTREE, Mass., and LIMONEST, France, Feb. 1 (HSMN NewsFeed) -- Haemonetics Corporation (NYSE: HAE) and Global Med...
Devices, Mergers & Acquisitions
Haemonetics, Global Med Technologies

Agreement Follows Recent Publication of Data for Lead Programs in ESRD, PAD CAMBRIDGE, Mass., Feb. 1 (HSMN NewsFeed) -- Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on th...
Biopharmaceuticals, FDA
Pervasis Therapeutics, Vascugel

Cordis to Receive $1.725 Billion BRIDGEWATER, N.J., Feb. 1 (HSMN NewsFeed) -- Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific resolving two Delaware litigations related to Cordis...
Devices, Litigation, Interventional Cardiology
Cordis, Johnson & Johnson, Palmaz, Jang patents

NATICK, Mass., Feb. 1 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX) today announced the settlement of three patent disputes with Johnson & Johnson (J&J). The disputes date back to 2003 and cover Boston Scientific's Jang patent and J&J's Pa...
Devices, Litigation, Interventional Cardiology
Boston Scientific, Cordis, Johnson & Johnson, Jang patent, Palmaz

New data published in demonstrate effective pregnancy prevention as compared to currently available emergency contraceptive options MORRISTOWN, N.J., Feb. 1 (HSMN NewsFeed) -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and HRA Pharma today announced an ...
Biopharmaceuticals, Licensing
Watson Pharmaceuticals, HRA Pharma, ulipristal acetate, emergency contraceptive

Expands Range of Products and Reach in Europe, Africa, and the Middle East Transaction Expected to be Immediately Accretive to Adjusted Earnings Per Share FRAZER, Pa., AESCH, Switzerland, and MAISONS-ALFORT, France, Feb. 1 (HSMN NewsFeed) -- Cephal...
Biopharmaceuticals, Mergers & Acquisitions
Cephalon, Mepha AG

ROCKVILLE, Md.--(HSMN NewsFeed)--Human Genome Sciences, Inc. (Nasdaq: HGSI ) today announced that Scott Habig has joined the Company as Vice President, Sales, reporting to Kevin P. McRaith, Vice President, Sales and Marketing, HGS. Mr. Habig was most recen...
Biopharmaceuticals, Personnel
Human Genome Sciences

PHILADELPHIA, Jan. 29 (HSMN NewsFeed) -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral t...
Biopharmaceuticals, Oncology, FDA
GlaxoSmithKline, TYKERB, lapatinib, metastatic breast cancer, breast cancer

RESEARCH TRIANGLE PARK, N.C., Jan. 29 (HSMN NewsFeed) -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration has approved Lamictal (lamotrigine) Extended-Release Tablets as once-a-day, add-on therapy for epilepsy in pat...
Biopharmaceuticals, Neurology
GlaxoSmithKline, Lamictal, Lamictal XR, lamotrigine, grand mal

PITTSBURGH, Jan. 29 (HSMN NewsFeed) -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Po...
Biopharmaceuticals, Generics, FDA
Mylan, Polyethylene Glycol 3350, Braintree Laboratories, GoLytely

PALM BEACH GARDENS, FL., Jan 29 --(HSMN NewsFeed)-- Eyetech Inc. announced today the results of a preliminary study assessing the investigational use of Macugen for macular edema secondary to branch retinal vein occlusion (BRVO) that were published in the ...
Biopharmaceuticals, Ophthalmology
Eyetech, Macugen, branch retinal vein occlusion

CHARLOTTESVILLE, Va., Jan. 29 (HSMN NewsFeed) -- Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed o...
Biopharmaceuticals, Venture Capital
Diffusion Pharmaceuticals

CASTLEFORD, England, January 29 (HSMN NewsFeed) -- We are pleased to announce the patent expiry launch of lercanidipine hydrochloride film-coated tablets, available in 10mg and 20mg strengths in packs of 28. Lercanidipine hydrochloride film-coated tablet...
Biopharmaceuticals, Generics
Teva UK, lercanidipine, Zanidip, Recordati, Teva Pharmaceutical

More than 50% Reduction of Restenosis Rate Compared to Standard PTA LEIPZIG, Germany--(HSMN NewsFeed)--Invatec, a comprehensive innovator of interventional products, welcomed the first clinical results of the Drug Eluting Balloon (DEB), IN.PACT Amphirio...
Devices, Interventional
Invatec, Drug Eluting Balloon, IN.PACT Amphirion, Critical Limb Ischemia

BALTIMORE, Jan. 28 (HSMN NewsFeed) -- Lupin Pharmaceuticals, Inc. (LPI) announced today that it has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its Perindopril Erbumine tablets, 2mg, 4mg and 8mg. Commercial shipment...
Biopharmaceuticals, Generics, FDA
Lupin Pharmaceuticals, Perindopril Erbumine, ACEON, Solvay Pharmaceuticals

Leader in Advanced Wound Bioengineered Alternative Tissues receives Clearance for Second Product CARLSBAD, Calif., Jan. 28 (HSMN NewsFeed) -- Aubrey Inc., an advanced wound care company, announced it has received clearance from the US Food and Drug Ad...
Devices, Wound Care, FDA
Aubrey Inc, AWBAT, wound dressing

SAN DIEGO--(HSMN NewsFeed)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX ), following approval of the transaction by Metabasis stockholders yesterday. As a r...
Biopharmaceuticals, Mergers & Acquisitions
Ligand Pharmaceuticals, Metabasis Therapeutics